Concert recording 2019-03-30c

[Track 1]. Kokopelli / Katherine Hoover -- [Track 2]. Mélodie in C-sharp minor, op. 4, no. 2 Notturno in G minor / Fanny Cecile Mendelssohn -- [Track 3]. Cowboy songs / Libby Larsen -- [Track 4]. Sound bytes. I. Invention II. Thirds III. Short circuit IV. Get up / Katherine Hoover -- [Track 5]. Overheard on a saltmarsh / Erin Goad -- [Track 6]. Sonatina for clarinet and piano / Caroline Schleicher Krämer -- [Track 7]. Winter spirits / Katherine Hoover -- [Track 8]. The butterfly from I never saw another butterfly / Lori Laitman -- [Track 9]. Erratic polka from Demented dances / Elizabeth Greener -- [Track 10]. Original Latin-American flute duets. I. Pasaje folia II. Torbellino III. Bolero Rhumba IV. Polka Chocoana / Carmen Liliana Marulanda -- [Track 11]. Trio for flute, oboe, and piano / Madeleine Dring

Analysis of Github Pull Requests

The popularity of the software repository site GitHub has created a rise in the Pull Based Development Models\u27 use. An essential portion of pull-based development is the creation of Pull Requests. Pull Requests often have to be reviewed by an individual to be approved and accepted into the Master branch of a software repository. The reviewing process can often be time-consuming and introduce a relatively high level of lost development time. This paper examines thousands of pull requests to understand the most valuable metadata of pull requests. We then introduce metrics in comparing the metadata of pull requests to understand what makes an effective pull request. Breaking pull requests into specific metadata pieces and evaluating what each piece brings to the whole allows us to review pull requests more efficiently. A pull request is successful if and only if it merges with the Master Branch. The Master Branch is the main branch of the code repository and is the production codebase. Using data analysis tools, we can determine which parts of a pull request are critical in its merge time. The formation of a framework and creating a data structure to track and manage development resources in the Pull Based Development Model

Concert recording 2019-04-07c

[Tracks 1-3]. Janus / Paul Hayden -- [Tracks 4-5]. Duo sonata / Gregory Wanamaker -- [Tracks 6-7]. Ciudades. Sarajevo Addis Ababa / Guillermo Lago -- [Track 8]. Pit band / William Albright -- [Tracks 9-10]. Crossroads songs / Evan Chambers -- [Track 11]. I encourage the bickering / Dan Puccio

A non-randomized dose-escalation Phase I trial of a protein-based immunotherapeutic for the treatment of breast cancer patients with HER2-overexpressing tumors

This Phase I dose-escalation study (NCT00058526) assessed the safety and immunogenicity of an anti-cancer immunotherapeutic (recombinant HER2 protein (dHER2) combined with the immunostimulant AS15) in patients with early-stage HER2-overexpressing breast cancer (BC). Sixty-one trastuzumab-naive patients with stage II-III HER2-positive BC received the dHER2 immunotherapeutic after surgical resection and adjuvant therapy. They were allocated into four cohorts receiving different doses of dHER2 (20, 100, 500 µg) combined with a fixed AS15 dose. Safety and immunogenicity (dHER2-specific antibody responses) were assessed. After completing the immunization schedule (three or six doses over 14 weeks) and a six-month follow-up, the patients were followed for 5 years for late toxicity, long-term immunogenicity, and clinical status. The immunizations were well tolerated, and increasing doses of dHER2 had no impact on the frequency or severity of adverse events. Few late toxicities were reported, and after 5 years 45/54 patients (83.3 %) were still alive, while 28/45 (62 %) with known disease status were disease free. Regarding the immunogenicity of the compound, a positive association was found between the dHER2 dose, the immunization schedule, and the prevalence of dHER2-specific humoral responses. Among the patients receiving the most intense immunization schedule with the highest dHER2 dose, 6/8 maintained their dHER2-specific antibody response 5 years after immunization. The dHER2 immunotherapeutic had an acceptable safety profile in early HER2-positive BC patients. dHER2-specific antibody responses were induced, with the rate of responders increasing with the dHER2 dose and the number and frequency of immunizations.status: publishe

A non-randomized dose-escalation phase i trial of a protein-based immunotherapeutic for the treatment of breast cancer patients with HER2-overexpressing tumors

This Phase I dose-escalation study (NCT000 58526) assessed the safety and immunogenicity of an anticancer immunotherapeutic (recombinant HER2 protein (dHER2) combined with the immunostimulant AS15) in patients with early-stage HER2-overexpressing breast cancer (BC). Sixty-one trastuzumab-naive patients with stage II–III HER2-positive BC received the dHER2 immunotherapeutic after surgical resection and adjuvant therapy. They were allocated into four cohorts receiving different doses of dHER2 (20, 100, 500 μg) combined with a fixed AS15 dose. Safety and immunogenicity (dHER2-specific antibody responses) were assessed. After completing the immunization schedule (three or six doses over 14 weeks) and a six-month follow-up, the patients were followed for 5 years for late toxicity, long-term immunogenicity, and clinical status. The immunizations were well tolerated, and increasing doses of dHER2 had no impact on the frequency or severity of adverse events. Few late toxicities were reported, and after 5 years 45/54 patients(83.3 %) were still alive, while 28/45 (62 %) with known disease status were disease free. Regarding the immunogenicity of the compound, a positive association was found between the dHER2 dose, the immunization schedule, and the prevalence of dHER2-specific humoral responses. Among the patients receiving the most intense immunization schedule with the highest dHER2 dose, 6/8 maintained their dHER2-specific antibody response 5 years after immunization. The dHER2 immunotherapeutic had an acceptable safety profile in early HER2-positive BC patients. dHER2-specific antibody responses were induced, with the rate of responders increasing with the dHER2 dose and the number and frequency of immunizations.SCOPUS: ar.jSCOPUS: ar.jinfo:eu-repo/semantics/publishe